COMP <GO>
GMED vs JNJ // EV/EBITDA & P/E VALUATION
Globus Medical Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: GMED 7
— JNJ 7
▲ EV/EBITDA & P/E VALUATION LEADER: GMED
LAST: $78.05 (-5.86%) • MKT CAP: $11.13B
valuation
17.6x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GMED VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GMED | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.40% | 67.90% | -0.50 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.70% | 25.50% | -16.80 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 17.6x | 18.5x | -0.90 | GMED | /valuation <GO> |
| Free Cash Flow Yield | 5.29% | 2.97% | +2.32 | GMED | /fcf-yield <GO> |
| Operating Margin | 16.30% | 34.70% | -18.40 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 18.30% | 28.50% | -10.20 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 16.70% | 6.00% | +10.70 | GMED | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.74 | 5.59 | +5.15 | GMED | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | GMED | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | GMED | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.0 | 60.4 | -11.32 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.08 | -0.01 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 23.0x | -5.60 | GMED | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.13B | $662.49B | -$651.36B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GMED REV | JNJ REV | GMED GROSS % | JNJ GROSS % | GMED FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.94B | $94.19B | 67.4% | 67.9% | $588.8M | $19.70B |
| FY 2024 | $2.52B | $88.82B | 58.9% | 69.1% | $405.2M | $19.84B |
| FY 2023 | $1.57B | $85.16B | 44.0% | 44.0% | $172.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GMED // BETA 1.07
JNJ // BETA 1.08